Cytokinetics EVP research & development sells $265,370 in stock
Fady Ibraham Malik, the Executive Vice President of Research & Development at Cytokinetics Inc., sold 3,500 shares of the company's common stock on August 18, 2026, for a total of $265,370. The sale price of $75.82 per share was near the stock's current trading level of $76.10, which has increased by 95% over the past year. Prior to this sale, Malik had purchased the same number of shares through the exercise of non-qualified stock options for $27,300.
Currently, Malik holds 153,902 shares of common stock and 30,386 non-qualified stock options. Despite Cytokinetics appearing overvalued relative to its Fair Value, 11 analysts have recently increased their earnings estimates. The company reported strong financial results for the second quarter of 2026, exceeding Wall Street expectations with $28.6 million in revenue and a narrower-than-expected loss of $1.50 per share.
The launch of their heart drug MYQORZO has been a key driver, with sales reaching $25.3 million, outperforming estimates by 65.2%. Several Wall Street analysts have raised their price targets for Cytokinetics, with Barclays increasing its target to $110 and Citizens to $110. Cytokinetics has also filed a lawsuit against Bristol-Myers Squibb and MyoKardia, alleging infringement on its MYQORZO patent. H.C. Wainwright maintains a Buy rating for the company, with a price target of $140.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
